Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
Commentary|Videos|June 2, 2026
Dr Mascarenhas on Data for Selinexor Plus Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Author(s)John O. Mascarenhas, MD
Fact checked by: Chris Ryan, Ashling Wahner
John Mascarenhas, MD, discusses key data from the SENTRY trial of selinexor plus ruxolitinib in JAK inhibitor–naïve myelofibrosis.
Advertisement
John Mascarenhas, MD, a professor of medicine at the Icahn School of Medicine at Mount Sinai, director of the Center of Excellence for Blood Cancers and Myeloid Disorders, and a member of Mount Sinai Tisch Cancer Center, discussed key data from the phase 3 SENTRY trial (NCT04562389) evaluating selinexor (Xpovio) plus ruxolitinib (Jakafi) in patients with JAK inhibitor–naïve myelofibrosis.
Advertisement
Related to this article
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
Advertisement
Advertisement
Trending on OncLive
1
The OncFive: Top Oncology Articles for the Week of 7/12
2
Five Under 5: Top Oncology Videos for the Week of 7/12
3
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
4
Imaging Cadence, Radiation Timing, and Osimertinib Dosing Frame CNS Management Decisions in EGFR-Mutated NSCLC
5